Today's Small-Cap Winners and Losers
Genta's (GNTA) shares were rising on news the Food and Drug Administration has accepted the biotech company's new drug application for the Genasense injection.
The company wants to use Genasense,
Genaera (GENR) saw its shares fall 5% after the company posted a fourth-quarter loss of $7.8 million, or 11 cents a share, on revenue of $42,000. The biopharmaceutical company lost $4.9 million, or 8 cents a share, with revenue of $29,000 in the year-ago period. Shares were losing 9 cents to $1.65.
Harris & Harris (TINY) was climbing after Punk Ziegel raised its price target on the venture capital company's stock to $19 from $16.50. Shares of Harris & Harris were up 87 cents, or 6.6%, to $14.09.MSGI Security Solutions (MSGI) advanced 3.3% after the company said it received contracts for security products and services with two foreign governments. The exact nature of the contracts in Europe and the broader Middle East are confidential. However, MSGI said the contracts establish long-term relationships that will result in at least $2 million in revenue over the next two years. Separately, MSGI has formally started operations in the Caribbean. Shares of MSGI were up 12 cents to $3.77. Shares of Carrington Laboratories (CARN) were skyrocketing after the company said its DelSite Biotechnologies unit selected Invitrogen's (IVGN) PD-Direct services to develop a process for a cell-based avian H5 influenza antigen that will be used in a nasal vaccine. DelSite is developing a nasal powder vaccine for pandemic avian influenza that combines its GelVac vaccine delivery system with an avian H5 influenza whole virion antigen. Carrington, a biopharmaceutical company, was jumping $1.79, or 39.5%, to $6.34. FX Energy (FXEN) shares were plunging following word from the company that the Drozdowice-1 well in western Poland will be plugged and abandoned. A drillstem test of the target reservoir yielded no observable hydrocarbons, FX said. The stock was dropping $1.03, or 18.6%, to $4.50.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV